MediWound reports 'positive' top-line results from the second cohort of its Phase 2 clinical trial evaluating EscharEx for debridement of dead or damaged tissue in diabetic foot ulcers and venous leg ulcers
The overall patient demographics and wound baseline characteristics were comparable across both arms. No related systemic adverse events were reported and adverse events related to local application were mild to moderate, reversible and resolved during the trial. Vital signs, pain scores, infection rates, laboratory parameters and blood loss were comparable between the two arms of the trial. Overall, no material safety concerns were identified.
- Co intends to initiate the EscharEx U.S. Phase 3 pivotal program in the first half of 2018
No comments:
Post a Comment